J Cutan Pathol 49(5):496499
One thing that does not get enough attention is that different GLP-1 receptor agonists cross the bloodbrain barrier at widely varying rates, and these differences could well explain why trial results have been so mixed
Retatrutides Phase 3 TRIUMPH-4 trial, published in December 2025, showed participants on the 12mg dose lost an average of 28.7% of their body weight over 68 weeks, with nearly 40% of participants losing 30% or more
however, cellular mechanisms related to the central nervous system, particularly glial cell dysfunction associated with astrocytes and microglia [25, 26] are among the most commonly proposed underlying explanations [4, 27, 28]
For weight loss medication costs specifically, the retatrutide cost guide and retatrutide buying guide cover pricing for this emerging compound
The effect of GLP-1 receptor agonists on anxiety: a systematic review